S&P/ASX Small Ordinaries (XSO) rose to 3,780.50, up 22.60 points (+0.60%) on Friday, but remains down 27.40 points (-0.72%) over the past five sessions. With small reporting season momentum winding down, expect more quarterly small-cap updates to hit the market today. As well as quarterlies, you can read about the following good work and more throughout the day.
Resolution Minerals
Resolution Minerals Ltd (ASX:RML, OTC:RLMLF)s maiden drill program at the 100%-owned Horse Heaven Gold–Antimony–Tungsten–Silver Project in Idaho has returned additional broad, near-surface gold intervals at the Golden Gate prospect. Assays from HH-GG25-002C and HH-GG25-003C, together with the previously reported HH-GG25-001C, confirm strong mineralisation from surface across multiple holes. HH-GG25-002C and HH-GG25-001C were drilled as fan holes from the same pad; HH-GG25-003C, about 75 metres to the northeast, extended the system along strike, indicating continuity and growth potential at Golden Gate.
Critical Resources
Critical Resources Ltd (ASX:CRR) has staked 438 additional claim cells at Mavis Lake in north-western Ontario, adding roughly 80 square kilometres (8,000 hectares). The expansion lifts the project footprint to ~400 square kilometres and extends key structural corridors viewed as prospective for spodumene-bearing pegmatites and orogenic gold. The larger land position enhances target density ahead of future exploration work.
Alkane Resources
At the Tomingley Gold Operations in central NSW, Alkane Resources Ltd (ASX:ALK, OTC:ALKEF) reported latest results from underground expansion and pre-mine grade control drilling around existing resources. The company says most deposits remain open at depth and along strike, with current underground and surface drill programs continuing across the site. The results support potential resource additions and mine-life extensions as Tomingley’s drill campaigns progress.
Anteris Technologies
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has received US Food and Drug Administration (FDA) approval to begin PARADIGM, its global Investigational Device Exemption (IDE) clinical trial evaluating the DurAVR® transcatheter heart valve (THV) in patients with severe calcific aortic stenosis, supporting a future PMA submission.
“We are extremely pleased to receive FDA approval for the PARADIGM trial, which allows us to commence patient recruitment in the United States. Together with the recent launch of the trial and first patients treated in Denmark, this is a significant step toward advancing this life-saving technology for people with aortic stenosis,” said vice chairman and CEO Wayne Paterson.
Imugene
Imugene Ltd (ASX:IMU, OTC:IUGNF)will issue 19,491,635 shares and pay US$3 million to Precision BioSciences after reaching the first milestone under their 2023 licence agreement for the azer-cel technology. The milestone was triggered by Imugene’s decision to begin discussions with the US FDA about a potential pivotal trial.
FireFly Metals
FireFly Metals Ltd (ASX:FFM, TSX:FFM, OTC:MNXMF) has appointed experienced resources executive and company director Leanne Heywood as an independent non-executive director. A Fellow of CPA Australia, Heywood’s career includes senior international copper marketing at Rio Tinto and a prior CFO role at a Rio Tinto copper operation.
Elixir Energy
Elixir Energy Ltd (ASX:EXR, OTC:ELXPF) has named Justin Ferravant as chief financial officer and company secretary, replacing Vicky Allinson, who has retired from finance and resigned from the role. Chair Richard Cottee said Allinson had made a significant contribution since listing and that Ferravant’s appointment aligns with the company’s shift toward commercialising its acreage.